What is Disclosure UK and why are we doing it?

Karen Borrer, Head of Corporate Communication

MedComms Networking Brunch Club, 1 November 2017, Oxford
The simple answer…

Type the beginning of an individual’s first name, last name, address, city, postal code, country, or a pharmaceutical company, or a healthcare organisation name or address.

Hint: If you are searching for John Graham Smith from Bristol, you can type ‘John Graham’, ‘John Smith’, or ‘Grah Smith’ or ‘John, Bristol’ using any combination of multiple search criteria.

Contact us at info@disclosureuk.org.uk

www.diclosureuk.org.uk
What is Disclosure UK?

• Disclosure UK is an online, searchable database that shows payments and benefits in kind – known as transfers of value (ToV) – made to healthcare professionals (HCPs), other relevant decision makers (ORDMs), and organisations (HCOs) for working in partnership with the pharmaceutical industry.

• It is part of a Europe-wide, pharmaceutical industry-led initiative, laid out in the European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Code and the ABPI Code of Practice for the Pharmaceutical Industry.

• It is something that pharmaceutical companies that are Code signatories must do annually in order to be compliant.
Data shown on Disclosure UK covers the key areas of collaboration between industry and HCPs, including:

- participation in advisory boards
- speaking at or chairing meetings
- working with and advising doctors and scientists in pharmaceutical companies
- speaking at conferences and symposia
- attending and contributing to national and international conferences
- participating in medical education and training funded by pharmaceutical companies.

It also shows ToVs for collaboration with HCOs including:

- provision of grants and donations
- sponsorship of events for the provision of medical education to HCPs.

In addition it shows the total amounts that pharmaceutical companies spend annually on research and development activities with HCPs and HCOs, most commonly in clinical trials.
Data analysis – 2015/2016

2015
109 companies
55% consent

2016
115 companies
65% consent

ToV amounts

<table>
<thead>
<tr>
<th>Category</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>£363m</td>
<td>£454m</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>£254m</td>
<td>£338m</td>
</tr>
<tr>
<td>Other ToV</td>
<td>£109m</td>
<td>£116m</td>
</tr>
</tbody>
</table>

www.disclosureuk.org.uk
But it’s more complicated…

www.disclosureuk.org.uk
The UK pharmaceutical industry has a long history of openness about its collaborations with HCPs, HCOs and patient organisations, dating back to the introduction of the first ABPI Code of Practice for the Pharmaceutical Industry published in 1958.

Disclosure UK is the latest step in this journey towards greater transparency about our relationships.
It’s impacting our reputation

Transparency remains a key driver for industry reputation – particularly in pricing and drug development. Disclosure plays a small but important role in that reputation development.

ComRes Reputation Audit 2016

> "We should be willing to disclose what has been received. You know, I've received payments, myself, for things and I'm happy to say that, and why. Where there are occasions where it's been from a single company, I think you have to accept that there is some conflict of interest, if you are transparent about that, I think that's okay."
> - HCP

> "I think it’s a good initiative. It will have some impact but nowhere near as much impact as some really good, strong, positive campaigns about the [industry’s] contribution to improving patient care and the economy."
> Patient Representative Group

**Importance of current industry initiatives**

*Showing NET: Important (1 – 10 on a scale where 0 = not at all important and 10 = very important)*

<table>
<thead>
<tr>
<th>Initiative</th>
<th>HCPs</th>
<th>Medical Students</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sharing good practice on how to conduct safe trials</td>
<td>72%</td>
<td>77%</td>
</tr>
<tr>
<td>Facilitating joint working projects between industry and NHS to support patient care</td>
<td>66%</td>
<td>69%</td>
</tr>
<tr>
<td>Providing material on Research and Development of new and innovative drugs</td>
<td>55%</td>
<td>74%</td>
</tr>
<tr>
<td>Campaigning for NICE to facilitate access to new innovative medicines</td>
<td>62%</td>
<td>69%</td>
</tr>
<tr>
<td>Committing to zero growth in the medicines bill through the Pharmaceutical Price Regulation Scheme (PPRS)</td>
<td>58%</td>
<td>66%</td>
</tr>
<tr>
<td>Working with Government to support NHS implementation of the recommendations of the Accelerated Access Review (AAR)</td>
<td>54%</td>
<td>68%</td>
</tr>
<tr>
<td>Providing interactive resources for school websites, with science content for students, teachers and parents, which supports the National Curriculum</td>
<td>51%</td>
<td>57%</td>
</tr>
<tr>
<td>Maintaining a central platform for the public disclosure of payments to health professionals</td>
<td>49%</td>
<td>65%</td>
</tr>
<tr>
<td>Providing secretarial support to the All-Party Parliamentary Group on Life Sciences</td>
<td>37%</td>
<td>36%</td>
</tr>
</tbody>
</table>

www.disclosureuk.org.uk
NHS England supports the development of Disclosure UK in bringing greater transparency to the relationships between HCPs and industry.

Its guidance* to staff and organisations on managing conflicts of interest suggests that:

…”organisations should seek to ensure that staff who are subject to wider transparency initiatives such as the ABPI Disclosure UK scheme are aware of and comply with them”…

(Doctors should) “Be open about any conflict of interest they face, declaring it formally when appropriate and as early as possible, in line with the policies of their employer or the organisation contracting their services.”

GMC Joint Statement on CoI

“We hope that more individuals and organisations do choose to be open about the payments and benefits they are receiving. Ultimately we would expect one hundred per cent take up because patients should know the basis on which their doctor is making a recommended treatment.”

AoMRC statement

“...we strongly encourage individuals to give their consent for payments they receive from the pharmaceutical industry to be disclosed as part of the ABPI Disclosure UK initiative...”

NICE CoI consultation document

*http://www.abpi.org.uk/our-work/disclosure/Pages/disclosure.aspx, accessed October 2017
The future of Disclosure UK

**2016 – 55%**
Data collected Jan – Dec 2015

**2017 – 65%**
Data collected Jan – Dec 2016

**2018 – 75%**
Data collected Jan – Dec 2017
- NHSE Col guidance in force June 2017
- AoMRC statement issued June 2017
- GMC statement issued August 2017

**2019 – 90%**
Data collected Jan – Dec 2018

**2020 – 100%**
Data collected Jan – Dec 2019

*Estimated consent rate*

100% target in 3 ‘publication’ years
More information?

If you would like more information please contact the Disclosure UK team:

info@disclosureuk.org.uk

0207 747 1410